世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
細胞・遺伝子治療CDMO市場規模、シェア、動向分析レポート：フェーズ別（前臨床、臨床）、製品タイプ別（遺伝子治療、遺伝子改変細胞治療、細胞治療）、適応症別（がん、感染症）、地域別、セグメント別予測、2024年～2030年Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product Type (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), By Indication (Oncology, Infectious Diseases), By Region, And Segment Forecasts, 2024 - 2030 細胞・遺伝子治療CDMO市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の細胞・遺伝子治療CDMO市場規模は2030年までに274.5億米ドルに達すると予測され、2024年から2030年までの年平... もっと見る
本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。 
サマリー細胞・遺伝子治療CDMO市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界の細胞・遺伝子治療CDMO市場規模は2030年までに274.5億米ドルに達すると予測され、2024年から2030年までの年平均成長率は27.9％と予測されている。細胞・遺伝子治療における研究開発活動の拡大、希少疾患への対応への注目の高まり、革新的な製品のパイプラインの拡大、この分野におけるアウトソーシングサービスに対するニーズの高まり、開発プロセスにおける継続的な技術進歩などが、この市場の需要増加の一因となっている。 さらに、新規細胞・遺伝子治療薬の開発に向けた民間・公的セクターからの投資や資金提供の増加も、市場の成長を支える重要な要因のひとつである。細胞・遺伝子治療市場への投資と資金提供の注目すべき例を以下にいくつか挙げる： - 2021年8月、遺伝子編集診断に特化した企業であるSeQure Dx社は、遺伝子治療薬を開発するために1750万米ドルのシリーズA資金調達ラウンドを発表した。この資金調達はMass General Brigham VenturesとRiverVest Venture Partnersが主導し、Casdin Capital、Digitalis Ventures、KdT Ventures、Alexandria Venture Investments、Bold Capital Partnersが参加した。 - 2021年8月、眼科疾患に対する非ウィルス性遺伝子治療に特化した臨床段階のバイオテクノロジー企業であるEyevensysは、シリーズBプラス資金調達ラウンドで1200万米ドルを確保した。 COVID-19パンデミックの初期段階は市場に悪影響を与えた。臨床試験活動全体の鈍化が大きな要因で、主に参加者とスタッフの安全性への懸念から、遅延や一時的な中断につながった。サプライチェーン管理、特に輸送とロジスティクスの混乱は課題をもたらし、パンデミックをめぐる不確実性は需要予測と実現可能性計画の全般的な欠如を生み出した。しかし、新たな規範への適応、サプライチェーンの回復力の強化、パンデミックによってもたらされた課題を乗り切るための安全対策の実施などを組み合わせることによって、市場は回復した。さらに、主要企業が採用した合併・買収戦略は、2021年までにパンデミックの悪影響を軽減するのに役立っている。 細胞・遺伝子治療CDMO市場レポートハイライト - 前臨床部門は2023年に66.2%の最大シェアを占める。細胞・遺伝子治療薬のパイプラインが増加していることが、このセグメントの成長を支える主な要因の一つである。 - 製品タイプ別では、細胞治療分野が2023年に41.6%の最大シェアを占めた。細胞治療サービスは、再生医療と個別化医療の進展に欠かせない - 希少疾患のCAGRは、分析期間を通じて28.4%と最も高くなると予測される。いくつかの希少疾患の有病率の増加は、細胞および遺伝子治療における研究開発活動の急増につながり、したがって、セグメントの成長を支えている。 - アジア太平洋地域のCAGRは予測期間中29.0%と最も高い。同地域の大幅な成長は、主にアジアのいくつかの経済圏で人件費と運営コストが低いため、細胞および遺伝子製品のコスト効率の高い製造に起因している。 目次Table of ContentsChapter 1. Research Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Segment Definitions 1.1.2. Phase 1.1.3. Product Type 1.1.4. Indication 1.2. Regional Scope 1.3. Estimates And Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.4.3. Objective - 3 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information Or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.9.2. Parent Market Analysis 1.10. List Of Secondary Sources 1.11. List Of Abbreviations Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth 3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics 3.2.1.3. Technological innovations across the cell & gene therapy development process 3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry 3.2.2. Market Restraint Analysis 3.2.2.1. Compliance with strict regulatory requirements 3.2.2.2. High development costs of CGT products 3.3. Cell and Gene Therapy CDMO Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier Power 3.3.1.2. Buyer Power 3.3.1.3. Substitution Threat 3.3.1.4. Threat Of New Entrant 3.3.1.5. Competitive Rivalry 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis 4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard 4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis 4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 - 2030 4.3.1. Pre-clinical 4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 4.3.2. Clinical 4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis 5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard 5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis 5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030 5.3.1. Gene Therapy 5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.1.2. Ex-vivo 5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.1.3. In-vivo 5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2. Gene-Modified Cell Therapy 5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.2. CAR T-cell therapies 5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.3. CAR-NK cell therapy 5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.4. TCR-T cell therapy 5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.5. Others 5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.3. Cell Therapy 5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis 6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard 6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis 6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030 6.3.1. Oncology 6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.2. Infectious Diseases 6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.3. Neurological Disorders 6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.4. Rare Diseases 6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.5. Others 6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. North America 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million) 7.4.2. U.S. 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 7.4.3. Canada 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 7.5. Europe 7.5.1. UK 7.5.1.1. Key Country Dynamics 7.5.1.2. Competitive Scenario 7.5.1.3. Regulatory Framework 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030 7.5.2. Germany 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030 7.5.3. France 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030 7.5.4. Italy 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 7.5.5. Spain 7.5.5.1. Key Country Dynamics 7.5.5.2. Competitive Scenario 7.5.5.3. Regulatory Framework 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030 7.5.6. Denmark 7.5.6.1. Key Country Dynamics 7.5.6.2. Competitive Scenario 7.5.6.3. Regulatory Framework 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030 7.5.7. Sweden 7.5.7.1. Key Country Dynamics 7.5.7.2. Competitive Scenario 7.5.7.3. Regulatory Framework 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 7.5.8. Norway 7.5.8.1. Key Country Dynamics 7.5.8.2. Competitive Scenario 7.5.8.3. Regulatory Framework 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030 7.6. Asia Pacific 7.6.1. Japan 7.6.1.1. Key Country Dynamics 7.6.1.2. Competitive Scenario 7.6.1.3. Regulatory Framework 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030 7.6.2. India 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030 7.6.3. China 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 7.6.4. South Korea 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030 7.6.5. Australia 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 7.6.6. Thailand 7.6.6.1. Key Country Dynamics 7.6.6.2. Competitive Scenario 7.6.6.3. Regulatory Framework 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030 7.7. Latin America 7.7.1. Brazil 7.7.1.1. Key Country Dynamics 7.7.1.2. Competitive Scenario 7.7.1.3. Regulatory Framework 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030 7.7.2. Mexico 7.7.2.1. Key Country Dynamics 7.7.2.2. Competitive Scenario 7.7.2.3. Regulatory Framework 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030 7.7.3. Argentina 7.7.3.1. Key Country Dynamics 7.7.3.2. Competitive Scenario 7.7.3.3. Regulatory Framework 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 7.8. MEA 7.8.1. South Africa 7.8.1.1. Key Country Dynamics 7.8.1.2. Competitive Scenario 7.8.1.3. Regulatory Framework 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030 7.8.2. Saudi Arabia 7.8.2.1. Key Country Dynamics 7.8.2.2. Competitive Scenario 7.8.2.3. Regulatory Framework 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 7.8.3. UAE 7.8.3.1. Key Country Dynamics 7.8.3.2. Competitive Scenario 7.8.3.3. Regulatory Framework 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030 7.8.4. Kuwait 7.8.4.1. Key Country Dynamics 7.8.4.2. Competitive Scenario 7.8.4.3. Regulatory Framework 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 Chapter 8. Competitive Landscape 8.1. Market Participant Categorization 8.1.1. Innovators 8.1.2. Market Leaders 8.1.3. Emerging Players 8.1.4. Company Market Share Analysis, 2023 8.2. Company Profiles 8.2.1. Lonza 8.2.1.1. Company Overview 8.2.1.2. Financial Performance 8.2.1.3. Service Benchmarking 8.2.1.4. Strategic Initiatives 8.2.2. Catalent, Inc 8.2.2.1. Company Overview 8.2.2.2. Financial Performance 8.2.2.3. Service Benchmarking 8.2.2.4. Strategic Initiatives 8.2.3. Cytiva 8.2.3.1. Company Overview 8.2.3.2. Financial Performance 8.2.3.3. Service Benchmarking 8.2.3.4. Strategic Initiatives 8.2.4. Samsung Biologics 8.2.4.1. Company Overview 8.2.4.2. Financial Performance 8.2.4.3. Service Benchmarking 8.2.4.4. Strategic Initiatives 8.2.5. Thermo Fisher Scientific Inc. 8.2.5.1. Company Overview 8.2.5.2. Financial Performance 8.2.5.3. Service Benchmarking 8.2.5.4. Strategic Initiatives 8.2.6. Novartis AG 8.2.6.1. Company Overview 8.2.6.2. Financial Performance 8.2.6.3. Service Benchmarking 8.2.6.4. Strategic Initiatives 8.2.7. WuXi AppTec 8.2.7.1. Company Overview 8.2.7.2. Financial Performance 8.2.7.3. Service Benchmarking 8.2.7.4. Strategic Initiatives 8.2.8. AGC Biologics 8.2.8.1. Company Overview 8.2.8.2. Financial Performance 8.2.8.3. Service Benchmarking 8.2.8.4. Strategic Initiatives 8.2.9. OmniaBio 8.2.9.1. Company Overview 8.2.9.2. Financial Performance 8.2.9.3. Service Benchmarking 8.2.9.4. Strategic Initiatives 8.2.10. Rentschler Biopharma SE 8.2.10.1. Company Overview 8.2.10.2. Financial Performance 8.2.10.3. Service Benchmarking 8.2.10.4. Strategic Initiatives 8.2.11. Charles River Laboratories 8.2.11.1. Company Overview 8.2.11.2. Financial Performance 8.2.11.3. Service Benchmarking 8.2.11.4. Strategic Initiatives
SummaryCell And Gene Therapy CDMO Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Research Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Segment Definitions 1.1.2. Phase 1.1.3. Product Type 1.1.4. Indication 1.2. Regional Scope 1.3. Estimates And Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.4.3. Objective - 3 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information Or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.9.2. Parent Market Analysis 1.10. List Of Secondary Sources 1.11. List Of Abbreviations Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth 3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics 3.2.1.3. Technological innovations across the cell & gene therapy development process 3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry 3.2.2. Market Restraint Analysis 3.2.2.1. Compliance with strict regulatory requirements 3.2.2.2. High development costs of CGT products 3.3. Cell and Gene Therapy CDMO Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier Power 3.3.1.2. Buyer Power 3.3.1.3. Substitution Threat 3.3.1.4. Threat Of New Entrant 3.3.1.5. Competitive Rivalry 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis 4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard 4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis 4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 - 2030 4.3.1. Pre-clinical 4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 4.3.2. Clinical 4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis 5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard 5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis 5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030 5.3.1. Gene Therapy 5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.1.2. Ex-vivo 5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.1.3. In-vivo 5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2. Gene-Modified Cell Therapy 5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.2. CAR T-cell therapies 5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.3. CAR-NK cell therapy 5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.4. TCR-T cell therapy 5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.2.5. Others 5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) 5.3.3. Cell Therapy 5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million) Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis 6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard 6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis 6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030 6.3.1. Oncology 6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.2. Infectious Diseases 6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.3. Neurological Disorders 6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.4. Rare Diseases 6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) 6.3.5. Others 6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million) Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. North America 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million) 7.4.2. U.S. 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 7.4.3. Canada 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 7.5. Europe 7.5.1. UK 7.5.1.1. Key Country Dynamics 7.5.1.2. Competitive Scenario 7.5.1.3. Regulatory Framework 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030 7.5.2. Germany 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030 7.5.3. France 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030 7.5.4. Italy 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 7.5.5. Spain 7.5.5.1. Key Country Dynamics 7.5.5.2. Competitive Scenario 7.5.5.3. Regulatory Framework 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030 7.5.6. Denmark 7.5.6.1. Key Country Dynamics 7.5.6.2. Competitive Scenario 7.5.6.3. Regulatory Framework 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030 7.5.7. Sweden 7.5.7.1. Key Country Dynamics 7.5.7.2. Competitive Scenario 7.5.7.3. Regulatory Framework 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 7.5.8. Norway 7.5.8.1. Key Country Dynamics 7.5.8.2. Competitive Scenario 7.5.8.3. Regulatory Framework 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030 7.6. Asia Pacific 7.6.1. Japan 7.6.1.1. Key Country Dynamics 7.6.1.2. Competitive Scenario 7.6.1.3. Regulatory Framework 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030 7.6.2. India 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030 7.6.3. China 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 7.6.4. South Korea 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030 7.6.5. Australia 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 7.6.6. Thailand 7.6.6.1. Key Country Dynamics 7.6.6.2. Competitive Scenario 7.6.6.3. Regulatory Framework 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030 7.7. Latin America 7.7.1. Brazil 7.7.1.1. Key Country Dynamics 7.7.1.2. Competitive Scenario 7.7.1.3. Regulatory Framework 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030 7.7.2. Mexico 7.7.2.1. Key Country Dynamics 7.7.2.2. Competitive Scenario 7.7.2.3. Regulatory Framework 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030 7.7.3. Argentina 7.7.3.1. Key Country Dynamics 7.7.3.2. Competitive Scenario 7.7.3.3. Regulatory Framework 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 7.8. MEA 7.8.1. South Africa 7.8.1.1. Key Country Dynamics 7.8.1.2. Competitive Scenario 7.8.1.3. Regulatory Framework 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030 7.8.2. Saudi Arabia 7.8.2.1. Key Country Dynamics 7.8.2.2. Competitive Scenario 7.8.2.3. Regulatory Framework 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 7.8.3. UAE 7.8.3.1. Key Country Dynamics 7.8.3.2. Competitive Scenario 7.8.3.3. Regulatory Framework 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030 7.8.4. Kuwait 7.8.4.1. Key Country Dynamics 7.8.4.2. Competitive Scenario 7.8.4.3. Regulatory Framework 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 Chapter 8. Competitive Landscape 8.1. Market Participant Categorization 8.1.1. Innovators 8.1.2. Market Leaders 8.1.3. Emerging Players 8.1.4. Company Market Share Analysis, 2023 8.2. Company Profiles 8.2.1. Lonza 8.2.1.1. Company Overview 8.2.1.2. Financial Performance 8.2.1.3. Service Benchmarking 8.2.1.4. Strategic Initiatives 8.2.2. Catalent, Inc 8.2.2.1. Company Overview 8.2.2.2. Financial Performance 8.2.2.3. Service Benchmarking 8.2.2.4. Strategic Initiatives 8.2.3. Cytiva 8.2.3.1. Company Overview 8.2.3.2. Financial Performance 8.2.3.3. Service Benchmarking 8.2.3.4. Strategic Initiatives 8.2.4. Samsung Biologics 8.2.4.1. Company Overview 8.2.4.2. Financial Performance 8.2.4.3. Service Benchmarking 8.2.4.4. Strategic Initiatives 8.2.5. Thermo Fisher Scientific Inc. 8.2.5.1. Company Overview 8.2.5.2. Financial Performance 8.2.5.3. Service Benchmarking 8.2.5.4. Strategic Initiatives 8.2.6. Novartis AG 8.2.6.1. Company Overview 8.2.6.2. Financial Performance 8.2.6.3. Service Benchmarking 8.2.6.4. Strategic Initiatives 8.2.7. WuXi AppTec 8.2.7.1. Company Overview 8.2.7.2. Financial Performance 8.2.7.3. Service Benchmarking 8.2.7.4. Strategic Initiatives 8.2.8. AGC Biologics 8.2.8.1. Company Overview 8.2.8.2. Financial Performance 8.2.8.3. Service Benchmarking 8.2.8.4. Strategic Initiatives 8.2.9. OmniaBio 8.2.9.1. Company Overview 8.2.9.2. Financial Performance 8.2.9.3. Service Benchmarking 8.2.9.4. Strategic Initiatives 8.2.10. Rentschler Biopharma SE 8.2.10.1. Company Overview 8.2.10.2. Financial Performance 8.2.10.3. Service Benchmarking 8.2.10.4. Strategic Initiatives 8.2.11. Charles River Laboratories 8.2.11.1. Company Overview 8.2.11.2. Financial Performance 8.2.11.3. Service Benchmarking 8.2.11.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Grand View Research社の医療機器分野での最新刊レポート
本レポートと同じKEY WORD（gene）の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
